50 related articles for article (PubMed ID: 38733402)
1. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial.
Römer T; Vokuhl C; Staatz G; Mottaghy FM; Christiansen H; Eble MJ; Timmermann B; Klussmann JP; Elbracht M; Calaminus G; Zimmermann M; Brümmendorf TH; Feuchtinger T; Kerp H; Kontny U
HNO; 2024 Jun; 72(6):423-439. PubMed ID: 38214716
[TBL] [Abstract][Full Text] [Related]
2. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
[TBL] [Abstract][Full Text] [Related]
3. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Liu X; Zhang Y; Yang KY; Zhang N; Jin F; Zou GR; Zhu XD; Xie FY; Liang XY; Li WF; He ZY; Chen NY; Hu WH; Wu HJ; Shi M; Zhou GQ; Mao YP; Guo R; Sun R; Huang J; Liang SQ; Wu WL; Su Z; Li L; Ai P; He YX; Zang J; Chen L; Lin L; Huang SH; Xu C; Lv JW; Li YQ; Hong SB; Jie YS; Li H; Huang SW; Liang YL; Wang YQ; Peng YL; Zhu JH; Zang SB; Liu SR; Lin QG; Li HJ; Tian L; Liu LZ; Zhao HY; Lin AH; Li JB; Liu N; Tang LL; Chen YP; Sun Y; Ma J
Lancet; 2024 May; ():. PubMed ID: 38824941
[TBL] [Abstract][Full Text] [Related]
4. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.
He Q; Luo X; Liu L; Zhao C; Li Z; Jin F
BMC Immunol; 2024 May; 25(1):28. PubMed ID: 38710996
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
Xu W; Qiu L; Li F; Fei Y; Wei Q; Shi K; Zhu Y; Luo J; Wu M; Yuan J; Liu H; Mao J; Cao Y; Zhou S; Guan X
Oral Oncol; 2024 May; 154():106865. PubMed ID: 38823173
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
Yao Y; Ouyang Q; Wang S; Li K; Luo Q; Qiu L; Liu F; Tan L; Li Q; Ren B; Long P; Ye J; Zhong X
Oral Oncol; 2024 May; 154():106867. PubMed ID: 38797001
[TBL] [Abstract][Full Text] [Related]
7. A nomogram based on the SII3 and clinical indicators predicts survival in patients with nasopharyngeal carcinoma treated with PD-1 inhibitors.
Chen X; Liang W; Wu X; Wang Y; Hong Y; Xie M; Han R; Lin Z
Medicine (Baltimore); 2024 May; 103(19):e38017. PubMed ID: 38728499
[TBL] [Abstract][Full Text] [Related]
8. SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis.
Huang X; Fang J; Huang L; Chen H; Chen H; Chai T; Ye Z; Chen H; Xu Q; Du Y; Yu P
Gastric Cancer; 2023 Nov; 26(6):1040-1050. PubMed ID: 37768447
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction.
Alarcón-Barrios S; Luvián-Morales J; Castro-Eguiluz D; Delgadillo-González M; Lezcano-Velázquez BO; Arango-Bravo EA; Flores-Cisneros L; Aguiar Rosas S; Cetina-Pérez L
Curr Probl Cancer; 2024 Feb; 48():101041. PubMed ID: 37988902
[TBL] [Abstract][Full Text] [Related]
10. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma.
Jiang W; Lv JW; Tang LL; Sun Y; Chen YP; Ma J
Cell Rep Med; 2024 May; ():101594. PubMed ID: 38843843
[TBL] [Abstract][Full Text] [Related]
11. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.
Ma BB; Hui EP; Chan AT
Cancer Sci; 2008 Jul; 99(7):1311-8. PubMed ID: 18498420
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
[TBL] [Abstract][Full Text] [Related]
13. Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches.
Lou PJ; Jacky Lam WK; Hsu WL; Pfeiffer RM; Yu KJ; Chan CML; Lee VCT; Chen TC; Terng SD; Tsou YA; Leu YS; Liao LJ; Chang YL; Chien YC; Wang CP; Lin CY; Hua CH; Lee JC; Yang TL; Hsiao CH; Wu MS; Tsai MH; Cheng HC; Hildesheim A; Chen CJ; Chan KCA; Liu Z;
J Clin Oncol; 2023 Sep; 41(26):4257-4266. PubMed ID: 37478397
[TBL] [Abstract][Full Text] [Related]
14. Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis.
Wu Q; Li S; Liu J; Zhong Y
Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5057-5069. PubMed ID: 35767064
[TBL] [Abstract][Full Text] [Related]
15. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
Zhang Y; Chen L; Hu GQ; Zhang N; Zhu XD; Yang KY; Jin F; Shi M; Chen YP; Hu WH; Cheng ZB; Wang SY; Tian Y; Wang XC; Sun Y; Li JG; Li WF; Li YH; Mao YP; Zhou GQ; Sun R; Liu X; Guo R; Long GX; Liang SQ; Li L; Huang J; Long JH; Zang J; Liu QD; Zou L; Su QF; Zheng BM; Xiao Y; Guo Y; Han F; Mo HY; Lv JW; Du XJ; Xu C; Liu N; Li YQ; Xie FY; Sun Y; Ma J; Tang LL
J Clin Oncol; 2022 Aug; 40(22):2420-2425. PubMed ID: 35709465
[No Abstract] [Full Text] [Related]
16. The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma.
Li XM; Zhang XM; Li JY; Jiang N; Chen L; Tang LL; Mao YP; Li WF; Zhou GQ; Li YQ; Liu N; Zhang Y; Ma J
Cancer Med; 2022 Sep; 11(18):3437-3444. PubMed ID: 35355438
[TBL] [Abstract][Full Text] [Related]
17. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.
Caudell JJ; Gillison ML; Maghami E; Spencer S; Pfister DG; Adkins D; Birkeland AC; Brizel DM; Busse PM; Cmelak AJ; Colevas AD; Eisele DW; Galloway T; Geiger JL; Haddad RI; Hicks WL; Hitchcock YJ; Jimeno A; Leizman D; Mell LK; Mittal BB; Pinto HA; Rocco JW; Rodriguez CP; Savvides PS; Schwartz D; Shah JP; Sher D; St John M; Weber RS; Weinstein G; Worden F; Yang Bruce J; Yom SS; Zhen W; Burns JL; Darlow SD
J Natl Compr Canc Netw; 2022 Mar; 20(3):224-234. PubMed ID: 35276673
[TBL] [Abstract][Full Text] [Related]
18. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.
Tang LL; Chen YP; Chen CB; Chen MY; Chen NY; Chen XZ; Du XJ; Fang WF; Feng M; Gao J; Han F; He X; Hu CS; Hu DS; Hu GY; Jiang H; Jiang W; Jin F; Lang JY; Li JG; Lin SJ; Liu X; Liu QF; Ma L; Mai HQ; Qin JY; Shen LF; Sun Y; Wang PG; Wang RS; Wang RZ; Wang XS; Wang Y; Wu H; Xia YF; Xiao SW; Yang KY; Yi JL; Zhu XD; Ma J
Cancer Commun (Lond); 2021 Nov; 41(11):1195-1227. PubMed ID: 34699681
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
